Month: January 2022

Fusion Round

Fusion Pharmaceuticals Announces Nomination Of First Targeted Alpha Therapy Candidate In Collaboration With AstraZeneca To Advance Into IND-Enabling Studies For Phase 1 Development.

Hamilton, Ontario, Canada and Boston, Massachusetts, USA.  10 January, 2022.  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced nomination of the first targeted alpha therapy (TAT) candidate under the Company’s collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN). Both companies will jointly develop through a Phase …

Fusion Pharmaceuticals Announces Nomination Of First Targeted Alpha Therapy Candidate In Collaboration With AstraZeneca To Advance Into IND-Enabling Studies For Phase 1 Development. Read More »

Cordella Pa Sensor

Endotronix Announces FDA Approval for PROACTIVE-HF Pivotal Trial Design Change to Single-Arm Study.

Lisle, Illinois, USA. 5 January 2022.  Seroba portfolio company, Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the U.S. Food and Drug Administration (FDA) has granted approval for an amendment to the company’s PROACTIVE-HF study, a pivotal Investigational Device Exemption (IDE) trial investigating …

Endotronix Announces FDA Approval for PROACTIVE-HF Pivotal Trial Design Change to Single-Arm Study. Read More »

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top